Chimerix to Present at H.C. Wainwright 24th Annual Global Investment Conference
Get Alerts CMRX Hot Sheet
Join SI Premium – FREE
DURHAM, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a pre-recorded corporate presentation at the H.C. Wainwright 24th Annual Global Investment Conference made available on Monday, September 12, 2022 at 7:00 a.m. ET.
An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.
CONTACT:Investor Relations: Michelle LaSpaluto919 972-7115[email protected]Will O’ConnorStern Investor Relations212-362-1200[email protected]
Source: Chimerix, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K
- Toll Brothers Announces Clubhouse Grand Opening Event on May 4 at Regency at Santa Rita Ranch 55+ Community in Liberty Hill, Texas
- THE CATALYST ACCELERATOR WINS STAGE ONE OF THE U.S. SMALL BUSINESS ADMINISTRATION’S 2024 GROWTH ACCELERATOR FUND COMPETITION
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!